 | |
| Clinical data | |
|---|---|
| Trade names | Astomin, Datosin, Gentus |
| Other names |
|
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.048.134 |
| Chemical and physical data | |
| Formula | C18H25N |
| Molar mass | 255.405 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Dimemorfan (INN;JANdimemorfan phosphate; also known asdimemorphan and3,17-dimethylmorphinan; brand namesAstomin,Dastosirr, andTusben) is anantitussive (cough suppressant) of themorphinan family that is widely used inJapan and is also marketed inSpain andItaly.[1][2][3][4] It was developed byYamanouchi Pharmaceutical (nowAstellas Pharma) and introduced in Japan in 1975.[3] It was later introduced in Spain in 1981 and Japan in 1985.[5]
Adverse effects include nausea, somnolence, dry mouth, and decreased appetite.[5]
Dimemorfan is ananalogue ofdextromethorphan (DXM) and itsactive metabolitedextrorphan (DXO), and similarly to them, acts as a potentagonist of theσ1 receptor (Ki = 151 nM).[6][7] However, unlike DXM and DXO, it does not act significantly as anNMDA receptor antagonist (Ki = 16,978 nM), and for this reason, lacksdissociative effects, thereby having reducedside effects andabuse potential in comparison.[8][9] Similarly to DXM and DXO, dimemorfan has only relatively lowaffinity for theσ2 receptor (Ki = 4,421 nM).[7]